Voskuil-Galoş Diana, Călinici Tudor, Piciu Andra, Nemeş Adina
Department of Medical Oncology, The Oncology Institute Prof. Dr. Ion Chiricuţă, Cluj-Napoca, Romania.
Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj-Napoca, Romania.
Front Oncol. 2024 Oct 7;14:1446953. doi: 10.3389/fonc.2024.1446953. eCollection 2024.
Following nephrectomy with curative intent, a subset of patients diagnosed with non-metastatic renal cell carcinoma (nmRCC) will present late recurrences, with metastatic relapses after 5 years from the surgical intervention. The aim of this study is to evaluate the prevalence of late recurrences in Romanian patients with nmRCC that have undergone surgery and to assess the clinicopathological characteristics prognostic for late-relapse RCC.
This is a single-center, retrospective and observational study that analyzed patients with nmRCC with clear cell histology who underwent surgical resection of the primary tumor with curative intent. The patients included in the study were treated and further surveilled according to a personalized follow-up plan between January 2011 and December 2012 in The Oncology Institute "Prof. Dr. Ion Chiricuţă", Cluj-Napoca, Romania. Study endpoints included median disease-free survival (DFS), median overall survival (OS), as well as evaluation of possible prognostic factors indicative of late relapse.
In the study cohort (n=51), the median DFS was 46 months and median OS was 130 months. DFS was significantly correlated with the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score (p=0.04, HR=2.48; 95% CI [1.02, 6.01]), neutrophil to lymphocyte ratio (NLR) (a higher NLR value was associated with a poorer DFS, p=0.035), tumor size (T4 tumors vs. T1 p<0.05, HR=9,81; 95% CI [2.65, 36.27]) and Fuhrman nuclear grade (Fuhrman grade 1 vs. Fuhrman grade 3 p<0.05, HR=4,16; 95% CI = [1.13,15.22]). Fifty one percent of the patients included experienced disease relapse. From this subgroup, a significant percentage of 42% patients presented disease recurrence after 60 months from nephrectomy. OS was correlated to IMDC score (p=0.049, HR=2.36; 95% CI [1, 5.58]) and Fuhrman nuclear grade (Fuhrman grade 1 vs. Fuhrman grade 3 p<0.05, HR=3,97; 95% CI [1.08, 14.54]).
The results of this study support the previously presented biological behavior of RCC, demonstrating that late recurrences in RCC are not uncommon occurrences and patients with localized RCC should be followed up for a longer interval after the surgery for the primary tumor. In addition, the study strengthens the data supporting certain biomarkers as valuable prognostic factors determining survival outcomes of patients with RCC.
在进行根治性肾切除术后,一部分被诊断为非转移性肾细胞癌(nmRCC)的患者会出现晚期复发,即在手术干预5年后出现转移性复发。本研究的目的是评估罗马尼亚nmRCC手术患者中晚期复发的发生率,并评估晚期复发肾细胞癌的临床病理特征对预后的影响。
这是一项单中心、回顾性观察研究,分析了具有透明细胞组织学的nmRCC患者,这些患者接受了根治性原发性肿瘤手术切除。2011年1月至2012年12月期间,在罗马尼亚克卢日-纳波卡的“伊翁·基里库察教授”肿瘤研究所,根据个性化随访计划对纳入研究的患者进行治疗并进一步监测。研究终点包括无病生存期(DFS)中位数、总生存期(OS)中位数,以及评估可能提示晚期复发的预后因素。
在研究队列(n = 51)中,DFS中位数为46个月,OS中位数为130个月。DFS与国际转移性肾细胞癌数据库联盟(IMDC)评分显著相关(p = 0.04,HR = 2.48;95% CI [1.02, 6.01])、中性粒细胞与淋巴细胞比值(NLR)(较高的NLR值与较差的DFS相关,p = 0.035)、肿瘤大小(T4肿瘤与T1肿瘤相比,p < 0.05,HR = 9.81;95% CI [2.65, 36.27])和富尔曼核分级(富尔曼1级与富尔曼3级相比,p < 0.05,HR = 4.16;95% CI = [1.13, 15.22])。纳入研究的患者中有51%经历了疾病复发。在这个亚组中,42%的患者在肾切除术后60个月出现疾病复发。OS与IMDC评分(p = 0.049,HR = 2.36;95% CI [1, 5.58])和富尔曼核分级(富尔曼1级与富尔曼3级相比,p < 0.05,HR = 3.97;95% CI [1.08, 14.54])相关。
本研究结果支持了先前提出的肾细胞癌生物学行为,表明肾细胞癌晚期复发并非罕见,局限性肾细胞癌患者在原发性肿瘤手术后应进行更长时间的随访。此外,该研究强化了支持某些生物标志物作为决定肾细胞癌患者生存结果的有价值预后因素的数据。